Skip to main content


CONRAD develops and tests innovative, user-centered technologies to improve sexual and reproductive health globally by enabling prevention of HIV/STI, unintended pregnancies, and maternal and neonatal disease. CONRAD pioneered the development of microbicides for HIV prevention and multipurpose prevention technologies that combine drugs with several mechanisms of action that provide contraception and HIV prevention. CONRAD developed three products to be tested within MATRIX, the cabotegravir injectable depot, the cabotegravir pellet implant, and the Tenofovir alafenamide/elvitegravir fast dissolving insert.

Key contacts

Gustavo F. Doncel
Meredith Clark
Melissa Donaghay

Read more about CONRAD by visiting their website at